Evaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors

Abstract Introduction  Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of laboratory physicians 2023-03, Vol.15 (1), p.020-024
Main Authors: Fatima, Maira, Sai Baba, Kompella S. S., Sreedevi, Neelam N. R., Kumar, Japa P., Raju, Gottumukkala S., Uppin, Shantveer G., Bhaskar, Madrol V., Khan, Siraj Ahmed, Iyyapu, Krishna M., Noorjahan, Mohammed
Format: Article
Language:English
Subjects:
breast cancer
breast tumor
CA 15–3
CEA
MAM
mammaglobin
Original
Original Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction  Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest to identify a better biomarker, we studied mammaglobin (MAM) in patients with breast cancer and benign breast tumors. Aim  To evaluate serum mammaglobin in breast cancer patients and compare it with benign breast tumor patients and healthy controls. To compare it with existing biomarkers serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3). Materials and methods: This is a cross-sectional, case–control study of 77 subjects, of which 27 were breast cancer patients, 20 benign breast tumor patients, and 30 healthy controls. Serum CEA and CA15–3 were estimated by electrochemiluminescence immunoassay (ECLIA) and mammaglobin (MAM) by enzyme-linked immunosorbent assay (ELISA). Results  Mammaglobin and CEA levels were elevated in breast cancer patients, followed by benign breast tumors when compared with controls ( P  
ISSN:0974-2727
0974-7826
DOI:10.1055/s-0042-1747678